As the past year has proven, the advancements in cell and gene therapy are increasing at a rapid pace and are transforming the way we think about medicine. Whether in research or in the clinic, scientific innovators are acutely aware that every moment counts when working with these valuable therapies. To facilitate knowledge sharing and collaboration, Thermo Fisher Scientific is proud to support the CAR-TCR Summit in Boston.
Thermo Fisher Scientific will showcase our comprehensive advanced therapy offering from booth #40, highlighting products and services that support the entirety of the workflow from discovery to cure. We are also participating in several insightful speaking sessions in the Discovery and the Transport, Logistics, and Supply Chain discussion tracks.
Discovery Track - Allogenic CAR-T Therapies, Xavier de Mollerat de Jeu, Director of R&D, Cell Biology/Transfection
Join Xavier as he walks through new viral and non-viral platforms for T-cell engineering, which will be highlighted by Thermo Fisher Scientific's offerings for delivery and gene editing tool for both cell and gene therapy applications.
Transport, Logistics, and Supply Chain Track – How to Mitigate Risk in the Advanced Therapy Supply Chain, Kristen Franklin, Client Services Manager, Cell Therapy
As the commercialization race heats up, many cell therapy developers are concerned with the supply chain and logistics scale-up challenges they will face when their product becomes commercial. Effective management of the advanced therapy supply chain is a complex challenge, but also critical to developing a successful commercial model.
Thermo Fisher Scientific offers integrated, scalable, and custom solutions to accelerate advanced therapy development to the clinic and beyond. We encourage you to attend our speaking sessions or swing by booth #40 to chat with our team of experts.
In the meantime, if you're interested in learning more about cell therapy development strategies and the role of the cold chain, download our webinar Cell Therapy: Achieving Success on the Road to Commercialization.